Skip to main content
ResMedNews

Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care

What happened

Resmed recently completed the acquisition of Noctrix Health to broaden its clinical sleep health portfolio.

Source

Article excerpt

Resmed RMD has entered into a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare Partners. The divestiture aligns with the company's long-term strategy to sharpen its focus on higher-growth opportunities across sleep health, breathing health and connected home-based care. The transaction is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary closing conditions. From an investor's perspective, the divestiture underscores Resmed's disciplined capital allocation strategy and reinforces its commitment to businesses with stronger long-term growth potential and higher scalability. By streamlining its portfolio and reallocating resources toward innovation in its core connected care ecosystem, the company is positioning itself to strengthen its competitive edge and drive sustainable value creation, while enabling MatrixCare to pursue growth under an owner dedicated to the long-term care software market. Shares of RMD have traded flat since the announcement on July 7. In the year-to-date period, shares of the company have lost 13.5% compared with the industry's 21.8% decline. The S&P 500 increased 9.5% in the same time frame. The divestiture is likely to strengthen Resmed's long-term growth profile by enabling the company to concentrate investments on its core sleep and breathing care...

Keep reading with a free account

The rest of this article, and every signal for ResMed, is in your free account.

Extracted from this sentence

Recently, Resmed completed the acquisition of Noctrix Health to broaden its clinical sleep health portfolio with the addition of Nidra Tonic Motor Activation Therapy, an FDA De Novo-classified, non-invasive treatment for moderate-to-severe Restless Legs Syndrome RLS.

Extracted by Autobound

From the Signal API record
Event
News

What this signalsIntegration work after a deal often opens needs for new systems and services.

Companies

  • Noctrix HealthTargetnoctrixhealth.com

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Jul 10, 2026
signal_type
news
signal_subtype
acquires

Use this data

Get every news signal for ResMed and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at ResMed this week?”

  2. Send it to your own tools

    The Signal API returns news signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/ba6d812a-4f43-6284-6d52-dfd98b37a545 returns this record as JSON. POST /v1/companies/enrich returns every signal for resmed.com.

{
  "signal_id": "ba6d812a-4f43-6284-6d52-dfd98b37a545",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-07-10T16:51:00+00:00",
  "company": {
    "name": "ResMed",
    "domain": "resmed.com"
  },
  "data": {
    "url": "https://sg.finance.yahoo.com/news/resmed-divests-matrixcare-business-sharpen-165100983.html",
    "title": "Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - Yahoo Finance Singapore",
    "excerpt": "Resmed RMD has entered into a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare Partners. The divestiture aligns with the company's long-term strategy to sharpen its focus on higher-growth opportunities across sleep health, breathing health and connected home-based care. The transaction is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary closing conditions. From an investor's perspective, the divestiture underscores Resmed's disciplined capital allocation strategy and reinforces its commitment to businesses with stronger long-term growth potential and higher scalability. By streamlining its portfolio and reallocating resources toward innovation in its core connected care ecosystem, the company is positioning itself to strengthen its competitive edge and drive sustainable value creation, while enabling MatrixCare to pursue growth under an owner dedicated to the long-term care software market. Shares of RMD have traded flat since the announcement on July 7. In the year-to-date period, shares of the company have lost 13.5% compared with the industry's 21.8% decline. The S&P 500 increased 9.5% in the same time frame. The divestiture is likely to strengthen Resmed's long-term growth profile by enabling the company to concentrate investments on its core sleep and breathing care...",
    "summary": "Resmed recently completed the acquisition of Noctrix Health to broaden its clinical sleep health portfolio.",
    "planning": false,
    "image_url": "https://s.yimg.com/lo/mysterio/api/E23E8CF2D43C1AD1629D857E1DBF202049A42965A3F185F99D8E284AB7D6A050/subgraphmysterio/resizefill_w1200_h756;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F529a2bf6a4c772f942409efa3808349b",
    "confidence": 0.9,
    "published_at": "2026-07-10T16:51:00Z",
    "article_sentence": "Recently, Resmed completed the acquisition of Noctrix Health to broaden its clinical sleep health portfolio with the addition of Nidra Tonic Motor Activation Therapy, an FDA De Novo-classified, non-invasive treatment for moderate-to-severe Restless Legs Syndrome RLS.",
    "related_company_name": "Noctrix Health",
    "related_company_domain": "noctrixhealth.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.